Sign in
NAMSW Stock Price, Chart, Stats & News
NewAmsterdam Pharma Company N.V.
Save
3.60B
Market cap
–
Current P/E
–
Forward P/E
NAMSW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.74% |
Operating margin | -1002.90% |
Pretax margin | -905.74% |
Net margin | -905.74% |
Effective tax rate | – |
ROA | -26.49% |
ROE | -27.47% |
D/E | 0.00x |
Interest coverage ratio | – |
NAMSW valuation
P/E | – |
P/S | 153.18x |
P/B | 5.02x |
P/CF | -23.21x |
P/FCF | -23.29x |
P/OCF | -23.21x |
PEG | -1.06x |
EV multiple | -16.25x |
About
NewAmsterdam Pharma Company N. V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP).
Similar securities
Based on sector and market capitalization
Report issue